Drug Profile
Factor VIII inhibitor bypassing fraction - Takeda
Alternative Names: Anti-inibitor coagulant complex - Takeda; FeibaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Baxter Healthcare Corporation
- Developer Baxter Healthcare Corporation; Takeda
- Class Antihaemorrhagics; Coagulants
- Mechanism of Action Blood coagulation factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilia; Haemophilia A; Haemophilia B
Most Recent Events
- 28 Nov 2022 Phase-III development is ongoing in Haemophilia in Croatia and Macedonia (IV) (NCT02764489)
- 27 Dec 2021 Baxalta completes a phase IIIb trial for Hemophilia in Croatia, Macedonia and Ukraine (IV) (NCT02764489)
- 28 Aug 2019 No recent reports of development identified for preclinical development in Haemophilia(New delivery system) in USA (IV, Injection)